Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chloride channel 7 alpha subunit (CLCN7) is a voltage-gated chloride ion channel and H^+/Cl^− antiporter highly expressed on lysosomal and late endosomal membranes, where it is essential for acidification of the lysosomal lumen and maintenance of organellar pH homeostasis[2][7][9]. It operates by exchanging chloride ions for protons across the membrane, a process critical for lysosomal enzyme function, endocytosis, and bone resorption by osteoclasts[2][7][9]. Mutations in CLCN7 cause autosomal dominant osteopetrosis type II, characterized by increased bone density due to defective bone resorption[2]. Broader roles include contributions to neurodegenerative processes, highlighting its importance for general lysosomal and neuronal health[2][7][9]. CLCN7 belongs to the CLC family of chloride channels and transporters, which mediates voltage-dependent transport of chloride across membranes as either channels or exchangers[5].
Modulation of H^+/Cl^− exchange, inhibition or dysfunction alters lysosomal pH and disrupts acidification-dependent cellular processes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chloride channel 7 alpha subunit (CLCN7).